Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- CSIMC Recommended Approval for Reimbursement on Piecework for 2 High-Priced Drugs
October 21, 2011
- Survey Finds Slight Increase in Generic Drug Dispensing Rate
October 21, 2011
- MHLW to Review Premium System Placing Priority on Premium for Pediatric Use
October 20, 2011
- Mr Kobayashi of Chuikyo Insists on NHI Price Reductions for New Generics
October 20, 2011
- MHLW Subcommittee Agrees on Access System for Domestically Unapproved Drugs
October 20, 2011
- MHLW Presents Data at Chuikyo Supporting Reduction in 70% Rule for New Generics
October 20, 2011
- Cost of Advanced Healthcare Services Totaled ¥13.2 Billion in FY2010: Korosho
October 20, 2011
- HSC Subcommittee Considering Review of Refractory Diseases Eligible for Treatment Subsidies
October 20, 2011
- MHLW Revises Precautions for Use in OTC Drugs
October 19, 2011
- PMDA Presents Warnings on Website to Prevent Mistaken Use of 3 Taxane Drugs
October 19, 2011
- Korosho Proposes 80% Price Rule for Single-enantiomer Drugs
October 19, 2011
- Korosho Presents Direction for PAL Amendment in 2012
October 19, 2011
- Council to Set Up Committee to Discuss Creation of “Drug Discovery Support Organization”
October 18, 2011
- MHLW to Survey, Consider Measures for Clinical Trials in Coping with Earthquakes
October 17, 2011
- Health Minister Shows Positive Attitude Towards Participation in TPP Talks
October 17, 2011
- Vice Minister Tsuji Supports Continuation of Premium for New Drug Development
October 17, 2011
- Korosho Task Force Discusses Upcoming Switch to Inactivated Polio Vaccine
October 17, 2011
- Avastin Approved for Treatment of Breast Cancer in Combination with Paclitaxel
October 13, 2011
- Revision of Ryotan-kisoku to Be Considered to Control Dispensing Point Services
October 13, 2011
- Chuikyo to Discuss “Dispensing Points” Offered by Pharmacies
October 12, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…